Large review finds no bone or joint effect from GLP-1 drugs, but lean mass falls

A systematic review and meta-analysis published September 12, 2026 in the journal Drugs found no effect of GLP-1 receptor agonists on bone mineral density or fractures and no significant change on joint measures, while reporting a consistent reduction in lean body mass and fat-free mass whose clinical meaning the authors say is still unresolved ^[1].

The analysis pooled 60 articles — 46 randomized controlled trials, 13 real-world evidence studies and one pharmacovigilance study — covering 1,250,717 individuals ^[1]. The authors searched MEDLINE, Cochrane CENTRAL and Embase from inception to March 2025, ran random-effects models for any outcome reported in at least two studies, and assessed the strength of evidence using GRADE ^[1]. The work was registered as PROSPERO record CRD420251024082 and is described by its authors as the first meta-analysis to examine GLP-1 receptor agonists across a broad panel of musculoskeletal outcomes ^[1].

The studies covered several drugs in this class, including semaglutide, liraglutide, exenatide, dulaglutide and tirzepatide, along with others ^[1]. People in the included studies were being treated for type 2 diabetes or obesity, the paper's stated uses for the drug class ^[1].

On bone, the analysis found no effect on bone mineral density at all sites or on fractures at all sites when the meta-analytic models used the most adjusted effect estimate ^[1]. On joints, models showed no significant change in scores for pain, physical function or stiffness on the Western Ontario and McMaster Universities Osteoarthritis Index, known as WOMAC ^[1].

The muscle finding came from 28 studies. The pooled standardized mean difference for lean body mass or fat-free mass was reported as 0.52, with a reported 95% confidence interval of −0.8 to −0.23, an I² of 88% and a p-value for heterogeneity below 0.0001 ^[1]. The authors report the result held in all sensitivity analyses and that no publication bias was found ^[1]. Subgroup analyses indicated the effect was mainly driven by liraglutide and semaglutide and appeared when GLP-1 receptor agonists were compared with placebo ^[1].

Despite the statistical consistency, the paper rates the certainty of this evidence as low and says the changes "appeared largely related to weight loss" ^[1]. The authors state that whether the lean-mass reductions translate into clinically meaningful impairments in muscle function or physical performance remains uncertain, and call for further studies looking at muscle function, strength or performance and using multivariate models that account for confounding ^[1]. The paper also notes that uncertainty persists about whether GLP-1 receptors are expressed in bone and skeletal muscle in a way that matters physiologically ^[1].

Why it matters for patients

Muscle, bone and joint concerns come up often for people considering or taking GLP-1 medications, and this analysis is the largest synthesis of that evidence to date ^[1]. Its bone and joint results point in a reassuring direction at the group level: across more than a million people, the pooled data did not show a bone density or fracture effect, and joint pain and function scores did not change significantly ^[1].

On muscle, the picture is less settled. A measurable drop in lean body mass and fat-free mass showed up consistently, but the review could not determine whether that translates into weaker muscles, worse physical performance or difficulty with daily tasks ^[1]. That is a gap in the evidence, not a finding of harm — and it is also not a finding of safety. The analysis did not test whether eating more protein, resistance training or any other specific strategy changes the outcome, and it offers no dose guidance ^[1].

It is also worth noting what a pooled average cannot say. These results describe groups of people, not any individual, and the review did not report how many participants experienced muscle-related symptoms ^[1].

What happens next

The paper lays out the authors' own next steps rather than any regulatory or trial milestone: studies that measure muscle function, strength or performance, and analyses that adjust for confounding factors ^[1]. No specific trial, timeline or review by regulators or guideline panels has been reported ^[1]. The analysis itself was published on September 12, 2026 ^[1].